fda warning letters compounded semaglutide tirzepatide 2024 2025 Troubling Findings in Study of GLP-1 Compounders FDA warns consumers not to

Despite their clinical uses, these drugs are strongly reinforcing, and their long-term use at high doses is linked with potential addiction, especially when they are rapidly administered or when high-potency forms are given

Early results from Grigsons team suggest that a related drug, liraglutide, reduces opioid cravings in people with opioid use disorder ( SN: 2/17/24 )

GLP-1 receptor agonists have shown promise in managing PCOS by tackling two of its most common challenges: insulin resistance and weight management

Lactis and inflammation, curcumin and inflammatory markers

Never Adjust Your Dose on Your Own It is very important that you never change your dose by yourself